Prostate cancer
UK grants early access to Novartis’ prostate cancer radioligand
Phil Taylor
Advanced Accelerator Applications, Early Access to Medicines Scheme, MHRA, Novartis, Pluvicto, Prostate cancer, Radiopharmaceutical, UK
0 Comment
Novartis gets first OK for radioligand Pluvicto in prostate cancer
Phil Taylor
Novartis, Oncology, Pluvicto, Prostate cancer, Radiopharmaceutical, regulatory approval
0 Comment
Merck trial of Keytruda, Lynparza combo in prostate cancer fails
Phil Taylor
AstraZeneca, immuno-oncology, Keytruda, Lynparza, Merck & Co, Oncology, Prostate cancer
0 Comment
Chasing rivals, Bayer files Nubeqa for new prostate cancer use
Phil Taylor
Bayer, Nubeqa, Oncology, Orion, Prostate cancer, regulatory
0 Comment
News/ News/ Sales and Marketing
Bayer triples sales forecast for prostate cancer drug Nubeqa
Phil Taylor
Bayer, Erleada, Financial, Nubeqa, Prostate cancer, Xtandi
0 Comment
After a Scottish aye, NICE says no to Lynparza for prostate cancer
Phil Taylor
AstraZeneca, HEOR, Lynparza, NICE, PARP inhibitor, Prostate cancer
0 Comment
Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer
Phil Taylor
Astellas, Bayer, Erleada, Johnson & Johnson, Nubeqa, Oncology, Pfizer, Prostate cancer, Xtandi
0 Comment
Helix web tool guides prostate cancer genetic testing
Phil Taylor
clinical decision-making, digital, digital health, Oncology, Prostate cancer
0 Comment